Sun Pharma’s phase 3 clinical studies evaluating ILUMYA in active psoriatic arthritis met their… EP News Bureau Jul 21, 2025 Treatment with tildrakizumab 100 mg (ILUMYA) resulted in greater improvements in PsA signs and symptoms at Week 24 compared to…
